Gynecologic Cancer CPG Mini-Module – A Case of Vulvar Melanoma

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Jyoti Bajpai, MBBS, MD, DM, of Tata Memorial Centre, Mumbai, India, presents a case study of pembrolizumab for metastatic vulvar melanoma. This case study addresses the relevance of the CPG recommendations for managing rare conditions like vulvar melanoma, necessary considerations when selecting resource-appropriate therapies in real-world situations, and studies supporting the use of supportive care or abbreviated courses of therapy when the standard of care is not available. This Mini-Module concludes with a discussion between Dr. Bajpai and Kunle Odunsi, MD, PhD, of University of Chicago Medicine on the need for more global collaboration to make immunotherapy accessible and affordable for patients around the world.

Run time: Approximately 14 minutes

Target Audience
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.